Flecainide API Manufacturers & Suppliers

Flecainide (CAS Number 54143-55-4) is a Class Ic antiarrhythmic agent belonging to the benzamide chemical class, characterized by a carboxamido substituent attached to a benzene ring. Originally synthesized in 1972 during efforts to develop novel anesthetics, the compound was later repurposed for cardiac arrhythmia treatment. Flecainide received regulatory approval from the FDA on October 31, 1985.

Clinically, flecainide is indicated for the prevention of supraventricular and ventricular arrhythmias, including paroxysmal atrial fibrillation and atrial flutter. It is approved for these indications in countries such as the United States and New Zealand. Its use is typically reserved for patients without significant structural heart disease or left ventricular systolic dysfunction due to safety concerns.

Pharmacodynamically, flecainide functions primarily as a potent sodium channel blocker, with additional inhibitory effects on potassium channels and cardiac ryanodine receptors. It binds to fast inward sodium channels and dissociates slowly during diastole, which prolongs the refractory period of cardiac tissue. This action helps to stabilize abnormal cardiac electrical activity by raising the threshold for depolarization and reducing ventricular excitability. Flecainide also inhibits delayed rectifier potassium channels, resulting in prolonged action potential duration in atrial and ventricular muscle fibers. Additionally, it modulates intracellular calcium release by blocking ryanodine receptor openings, thereby reducing cellular depolarization.

Pharmacokinetic properties allow for once-daily dosing due to its long duration of action. Flecainide has a narrow therapeutic index, necessitating careful dosing and monitoring. It is metabolized partly by cytochrome P450 enzymes, including CYP1A2, CYP2C9, and CYP2D6, and demonstrates inhibitory activity on these isoforms. Flecainide is also a substrate and inhibitor of membrane transporters such as MATE1 and P-glycoprotein. These characteristics contribute to potential drug-drug interactions and require cautious use in polypharmacy settings.

Safety considerations include contraindication in patients with underlying structural heart disease or significant left ventricular dysfunction due to increased proarrhythmic risk. It is classified as a moderate risk agent for QT interval prolongation and has negative inotropic effects, warranting cardiac function monitoring during therapy.

Notable marketed products containing flecainide include commercially available tablets under various brand names, used predominantly in outpatient management of arrhythmias.

From a sourcing and quality perspective, procurement of flecainide API demands rigorous compliance with pharmacopeial standards and regulatory guidelines to ensure purity, potency, and batch-to-batch consistency. Given its narrow therapeutic index and complex metabolic profile, impurities and enantiomeric purity must be tightly controlled. Manufacturers and sourcing managers should ensure suppliers provide comprehensive analytical data and adhere to good manufacturing practices (GMP) to mitigate risks in drug product formulation and patient safety.